SHERWOOD, OR September 24, 2013 -- Entia Biosciences (Entia; OTCQB: ERGO), a food science biotechnology company and emerging leader in the field of Nutrigenomics, has engagedBioCheck Inc., of Foster City, California to develop a family of monoclonal and polyclonal antibodies and enzyme-linked immunosorbent assays (ELISA) that can be used to diagnose deficiencies of important dietary nutrients in human tissue, serum, plasma, and urine. The companies will initially focus on the development of proprietary antibodies and assays for L-Ergothioneine (Ergo) and to Leukocyte 8-Hydroxydeoxyguanosine (8-OHdG). When approved for use, these new tests are expected help physicians cost-effectively measure changes in these biomarkers and determine if Entia’s medical foods will be an appropriate and beneficial therapy for patients.
Ergo is a potent amino acid and electron donating antioxidant that is acquired exclusively from the diet and carried by a unique and specific transporter (human gene symbol SLC22A4) into cells throughout the body that are fighting damage and death from oxidative stress and toxic free radical reactions. Drs. Paul and Snyder of Johns Hopkins University School of Medicine have suggested that Ergo is as potent as glutathione and because of its dietary origin and the toxicity associated with its depletion, it may represent a new vitamin whose physiologic roles include antioxidant cytoprotection. These doctors further believe that the high density of Ergo within mitochondria implies a unique role in protecting mitochondrial DNA from damage induced by free radicals and reactive oxygen species (Paul & Snyder, 2009). Entia acquired the world-wide exclusive diagnostic and therapeutic rights to the Ergo Transporter (ETT) from the University of Cologne (Germany) in 2010 and has filed patents on the use of Ergo in the treatment of anemia, diabetes, auto-immune diseases, and neurodegenerative diseases.
8-OHdG is an indicator of oxidative stress, impaired metabolism, and mitochondrial dysfunction and is a biomarker that is excised during repair of oxidative damage to DNA. Studies have observed increases in 8-OHdG levels in anemia (Honda, 2000), diabetes (Wu, 2004), stroke and several important neurodegenerative diseases (Mariani, 2005), including mild cognitive impairment, Parkinson's disease, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Huntington’s disease (Long, 2012), and Autism (Kern, 2013).
"The unique proprietary technologies of Entia Biosciences and BioCheck will be used to create a ‘Companion Diagnostic’ platform that will provide important biological and/or clinical information, enable better decisions in the application of medical foods in personalized medicine, and improve the early intervention and prevention of serious medical conditions that are currently running unchecked," stated Marvin S. Hausman MD, CEO, Entia Biosciences. “Dr. Chen and the team at BioCheck have been involved in the development of a number of widely used diagnostics that have been approved for marketing by the FDA, including the first rapid pregnancy test, and we are excited that they share our vision for the use of bionutrients to regulate the onset, progression, and amelioration of debilitating diseases.”
About BioCheck Inc.
Founded in 1997 by Dr. John Chen, Ph.D., BioCheck specializes in the development of custom enzyme immunoassay kits, antibody purification and conjugation, contract manufacturing and assembly.
About Entia Biosciences, Inc.
Entia is an authority on the clinical effects of oxidative stress and free radical reactions and is bringing this expertise to the fields of food science biotechnology and Nutrigenomics. The Company identifies, scientifically validates, patents, and commercializes solutions that address multi-billion dollar markets for health, beauty and agriculture.
For more information, please visit our web sites at www.entiabio.com or contact:
Chief Operating Officer
Entia Biosciences, Inc.
13565 SW Tualatin-Sherwood Rd Sherwood, OR, 97140
Phone: 503-334-3575, Email: email@example.com
Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the transaction described in this press release, and other risks identified in the filings byEntia Biosciences with the Securities and Exchange Commission. Further information on risks faced by the Company and its shareholders are detailed in the Form 10-K for the year ended December 31, 2012 and in its subsequent Quarterly Reports on Form 10-Q. These filings are or will become available on a website maintained by the Securities and Exchange Commission at http://www.sec.gov. The information contained in this press release is accurate as of the date indicated. Actual results, events or performance may differ materially. Entia does not undertake any obligation to publicly release the result of any revision to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Honda M, Yamada Y, Tomonaga M, Ichinose H, Kamihira S.(2000). Correlation of urinary 8-hydroxy-2'-deoxyguanosine (8-OHdG), a biomarker of oxidative DNA damage, and clinical features of hematological disorders: a pilot study. Leuk. Res., 24(6):461-8.
Kern JK, Geier DA, Sykes LK, and Geier MR (2013). Evidence of neurodegeneration in autism spectrum disorder. Published online 2013 August 8. doi: 10.1186/2047-9158-2-17
Long JD, Matson WR, Juhl AR, Leavitt BR, Paulsen JS; PREDICT-HD Investigators and Coordinators of the Huntington Study Group (2012). 8OHdG as a marker for Huntington disease progression. Neurobiol Dis.,46(3):625-34.
Mariani E., Polidori M. C., Cherubini A., Mecocci P. (2005). Oxidative stress in brain aging, neurodegenerative and vascular diseases: an overview. J.Chromatogr. B Analyt. Technol. Biomed. Life Sci., 827: 65–75.
Paul, B. & Snyder, S., (2009). The Unusual Amino Acid L-Ergothioneine is a Physiologic Cytoprotectant. Cell Death & Differentiation, pp. 1-7.
Wu LL, Chiou CC, Chang PY, Wu JT.(2004) Urinary 8-OHdG: a marker of oxidative stress to DNA and a risk factor for cancer, atherosclerosis and diabetics. Clin Chim Acta., 339(1-2):1-9.
SOURCE Entia Biosciences